Cutaneous reactions to chemotherapy and their management

American Journal of Clinical Dermatology

Volumn 7, Issue 1, 2006, Pages 45-63

  Wyatt, Angela J ^a   Leonard, Gregory D ^b   Sachs, Dana L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIDOTE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CALCINEURIN INHIBITOR; CETUXIMAB; CISPLATIN; CORTICOSTEROID; CYTARABINE; DACTINOMYCIN; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; HYDROXYUREA; IMUVERT; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PALIFERMIN; PETROLATUM; PODOPHYLLIN; PYRIDOXINE; RETINOID; TAXANE DERIVATIVE; TETRACYCLINE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; XIPAMIDE;

ABSCESS; ACNE; ACTINIC KERATOSIS; ALOPECIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTERITIS; ARTERY EMBOLISM; ASCITES; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BREAST CANCER; BULLOUS SKIN DISEASE; CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONDYLOMA ACUMINATUM; CORRELATION ANALYSIS; DARIER DISEASE; DELAYED HYPERSENSITIVITY; DERMATOMYOSITIS; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EDEMA; EOSINOPHILIA; ERYTHEMA; ERYTHEMA MULTIFORME; EXTRAVASATION; FLUID RETENTION; FLUSHING; FOLLICULITIS; GYNECOMASTIA; HAIR DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HIDRADENITIS; HUMAN; HYPERPIGMENTATION; INTERTRIGO; KINKY HAIR; LEG EDEMA; LEG ULCER; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; MEASLES LIKE RASH; MEDLINE; MELANONYCHIA; METASTASIS; MORBIDITY; MOUTH CARCINOMA; MOUTH ULCER; MOUTHWASH; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NONHUMAN; NOSE ULCER; ONYCHOLYSIS; ORAL MUCOSAL DISEASE; PAPULE; PARONYCHIA; PEMPHIGUS; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHOTOALLERGY; PLEURA EFFUSION; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; RADIATION INJURY; RASH; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIDE EFFECT; SKIN ALLERGY; SKIN ATROPHY; SKIN CANCER; SKIN FIBROSIS; SKIN MANIFESTATION; SKIN NECROSIS; SKIN TOXICITY; SKIN ULCER; SORE THROAT; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; STOMATITIS; SYMPTOMATOLOGY; TOXIC EPIDERMAL NECROLYSIS; TOXICITY; TRICHOMEGALY; URTICARIA; VASCULITIS; VEIN EMBOLISM; VERRUCA PLANTARIS; VESICULAR RASH; XEROSIS;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; HUMANS; NEOPLASMS;

EID: 33644555585     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200607010-00005     Document Type: Review

References (181)

1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-43
3. Bunn Jr PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29 (5 Suppl. 14): 38-44
4. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004; 84: 23-6
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58
6. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003; 17 (11 Suppl. 12): 23-8
7. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11
8. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29 (1 Suppl. 4): 27-36
9. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-76
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab synplus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
11. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475-80
12. Epstein Jr EH, Lutzner MA. Folliculitis induced by actinomycin D. N Engl J Med 1969; 281: 1094-6
13. Leo S, Tatulli C, Taveri R, et al. Dermatological toxicity from chemotherapy containing 5-fluorouracil. J Chemother 1994; 6: 423-6
14. Cetkovska P, Pizinger K, Cetkovsky P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol 2002; 16: 481-5
15. Litt JZ. Drug eruption reference manual. 9th ed. New York (NY): Parthenon Publishing Group Inc., 2003
16. Grem JL. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. Oncology (Williston Park) 2001; 15 (1 Suppl. 2): 13-9
17. Laack E, Mende T, Knuffmann C, et al. Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine. Ann Oncol 2001; 12: 1761-3
18. Vassallo C, Passamonti F, Merante S, et al. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001; 26: 141-8
19. Feizy V, Namazi MR, Barikbin B, et al. Methotrexate-induced acral erythema with antibullous reaction. Dermatol Online J 2003; 9: 14
20. Hellier I, Bessis D, Sotto A, et al. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132: 590-1
21. Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131: 202-6
22. Portal I, Cardenal F, Garcia-del-Muro X. Etoposide-related acral erythema. Cancer Chemother Pharmacol 1994; 34: 181
23. Vakalis D, Ioannides D, Lazaridou E, et al. Acral erythema induced by chemotherapy with cisplatin. Br J Dermatol 1998; 139: 750-1
24. Brown J, Burck K, Black D, et al. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991; 24 (6 Pt 1): 1023-5
25. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34
26. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf 2001; 24: 353-67
27. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63
28. Katoh M, Kadota M, Nishimura Y. A case of docetaxel-induced erythrodysesthesia. J Dermatol 2004; 31: 403-6
29. Lombardi D, Crivellari D, Scuderi C, et al. Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study. Tumori 2004; 90: 285-8
30. Fontana JA. Radiation recall associated with VP-16-213 therapy. Cancer Treat Rep 1979; 63: 224-5
31. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625-31
32. Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol 2004; 31: 147-60
33. Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001; 46: 110-6
34. Blumenreich MS, Woodcock TM, Richman SP, et al. A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. Cancer 1985; 56: 256-8
35. Hussein AM, Jimenez JJ, McCall CA, et al. Protection from chemotherapy-induced alopecia in a rat model. Science 1990; 249: 1564-6
36. Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J 1993; 86: 489-96
37. Hussein AM. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model. Int J Dermatol 1995; 34: 470-3
38. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. Arch Dermatol 2002; 138: 1149-55
39. Vanhooteghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol 2001; 18: 249-51
40. Passiu G, Cauli A, Atzeni F, et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999; 18: 422-4
41. Dacey MJ, Callen JP. Hydroxyurea-induced dermatomyositis-like eruption. J Am Acad Dermatol 2003; 48: 439-41
42. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997; 36 (2 Pt 1): 178-82
43. Kupfer I, Balguerie X, Courville P, et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol 2003; 48: 279-81
44. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001; 19: 197-200
45. Cleveland MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer 2000; 88: 1078-81
46. Lo SK, Yip D, Leslie M, et al. 5-fluorouracil-induced erythema multiforme. Int J Clin Pract 1999; 53: 219-21
47. Hirai K, Ishiko O, Nakajima S, et al. Local erythematous dermatitis after intravenous docetaxel. Gynecol Obstet Invest 2002; 53: 118-20
48. Harrison PV. Methotrexate-induced epidermal necrosis. Br J Dermatol 1987; 116: 867-9
49. Sommers KR, Kong KM, Bui DT, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs 2003; 14: 659-62
50. Lowndes S, Darby A, Mead G, et al. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-50
51. Arias D, Requena L, Hasson A, et al. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. J Cutan Pathol 1991; 18: 344-6
52. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing. Arch Dermatol 2003; 139: 85-6
53. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003; 139: 39-43
54. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6
55. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol 2004; 15: 858-62
56. Cox RF. Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm 1984; 41: 2410-4
57. Fitzpatrick JE, Yokel BE, Hood AF. Mucocutaneous complications of antineoplastic therapy. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York (NY): McGraw-Hill, 1999: 1649.
58. Baer D, Wilkinson LS. Daunomycin, adriamycin, and recall effect. Ann Intern Med 1976; 85: 259-60
59. Forte FA. Vincristine neuropathy [letter]. JAMA 1974; 227: 325
60. Dorr RT, Alberts DS. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. J Natl Cancer Inst 1985; 74: 113-20
61. Bertelli G, Dini D, Forno GB, et al. Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. J Cancer Res Clin Oncol 1994; 120: 505-6
62. Parashos PJ. A rational approach for the management of tissue extravasation due to antineoplastic drugs. Microlink Update 1986; 2: 13-5
63. Bellone JD. Treatment of vincristine extravasation [letter]. JAMA 1981; 245: 343
64. Olver IN, Aisner J, Hament A, et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6: 1732-5
65. Lawrence JH, Walsh D, Zapotowski KA, et al. Topical dimethyl sulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol 1989; 23: 316-8
66. Ludwig CV, Stoll HR, Obrist R, et al. Prevention of cytotoxic drug induced skin ulcers with dimethyl sulfoxide (DMSO) and alpha-tocopherol. Eur J Cancer Clin Oncol 1987; 23: 327-9
67. Nobbs P, Barr RD. Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. Br J Cancer 1983; 48: 873-6
68. Van Raalte J, Rice C, Moss CE. Visible-light system for detecting doxnoid orubicin contamination on skin and surfaces. Am J Hosp Pharm 1990; 47: 1067-74
69. Andersson AP, Dahlstrom KK. Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer 1993; 29A: 1712-4
70. Rentschler R, Wilbur D. Pyridoxine: a potential local antidote for mitomycin-C extravasation. J Surg Oncol 1988; 37: 269-71
71. Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4: 41-60
72. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12: 245-55
73. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985; 75: 397-405
74. Berghammer P, Pohnl R, Baur M, et al. Docetaxel extravasation. Support Care Cancer 2001; 9: 131-4
75. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45: 438-41
76. Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11: 270-7
77. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-100
78. Lautenschlager S, Itin PH. Reticulate, patchy and mottled pigmentation of the neck: acquired forms. Dermatology 1998; 197: 291-6
79. Aste N, Fumo G, Contu F, et al. Nail pigmentation caused by hydroxyurea: report of 9 cases. J Am Acad Dermatol 2002; 47: 146-7
80. Hernandez-Martin A, Ros-Forteza S, de Unamuno P. Longitudinal, transverse, and diffuse nail hyperpigmentation induced by hydroxyurea. J Am Acad Dermatol 1999; 41 (2 Pt 2): 333-4
81. Jeevankumar B, Thappa DM. Blue lunula due to hydroxyurea. J Dermatol 2003; 30: 628-30
82. Schrijvers D, Van Den Brande J, Vermorken JB. Supravenous discoloration of the skin due to docetaxel treatment. Br J Dermatol 2000; 142: 1069-70
83. Shah PC, Rao KR, Patel AR. Cyclophosphamide-induced nail pigmentation [letter]. Lancet 1975; II: 548-9
84. Kroumpouzos G, Travers R, Allan A. Generalized hyperpigmentation with daunorubicin chemotherapy. J Am Acad Dermatol 2002; 46 (2 Suppl.): 1-3
85. Krutchik AN, Buzdar AU. Pigmentation of the tongue and mucous membranes associated with cancer chemotherapy. South Med J 1979; 72: 1615-6
86. Abess A, Keel DM, Graham BS. Flagellate hyperpigmentation following intraleic sional bleomycin treatment of verruca plantaris. Arch Dermatol 2003; 139: 337-9
87. Miori L, Vignini M, Rabbiosi G. Flagellate dermatitis after bleomycin: a histological and immunohistochemical study. Am J Dermatopathol 1990; 12: 598-602
88. Marcoux D, Anex R, Russo P. Persistent serpentine supravenous hyperpigmented eruption as an adverse reaction to chemotherapy combining actinomycin and vincristine. J Am Acad Dermatol 2000; 43: 540-6
89. Robak T, Blasinska-Morawiec M, Krykowski E, et al. 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases. Eur J Haematol 1997; 59: 216-20
90. Moon C, Verschraegen CF, Bevers M, et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11: 565-8
91. Tucci E, Pirtoli L. Etoposide-induced hypersensitivity reactions: report of two cases. Chemioterapia 1985; 4: 460-2
92. Kasperek C, Black CD. Two cases of suspected immunologic-based hypersensitivity reactions to etoposide therapy. Ann Pharmacother 1992; 26: 1227-30
93. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24: 253-62
94. Siderov J, Prasad P, De Boer R, et al. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86: 2-3
95. Bernstein BJ, Troner MB. Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide. Pharmacotherapy 1999; 19: 989-91
96. Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130: 25-8
97. Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21: 4611-4
98. Thong BY, Leong KP, Thumboo J, et al. Cyclophosphamide type I hypersensitivity in systemic lupus erythematosus. Lupus 2002; 11: 127-9
99. Minami R, Hirase N, Motomura S, et al. Anaphylactoid reaction to cyclophosphamide in a patient with T cell lymphoma and hemophagocytic syndrome. Int J Hematol 1999; 69: 57-8
100. Salles G, Vial T, Archimbaud E. Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. Ann Hematol 1991; 62: 74-5
101. Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. Arch Intern Med 1984; 144: 2267
102. Collins JA. Hypersensitivity reaction to doxorubicin. Drug Intell Clin Pharm 1984; 18: 402-3
103. Vogelzang NJ. "Adriamycin flare": a skin reaction resembling extravasation. Cancer Treat Rep 1979; 63: 2067-9
104. Young PC, Montemarano AD, Lee N, et al. Hypersensitivity to paclitaxel manifested as a bullous fixed drug eruption. J Am Acad Dermatol 1996; 34 (2 Pt 1): 313-4
105. Porzio G, Marchetti P, Paris I, et al. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 2002; 23: 335-6
106. Ottaiano A, Tambaro R, Greggi S, et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 2003; 23: 3465-8
107. Libra M, Sorio R, Buonadonna A, et al. Cisplatin may be a valid alternative approach in ovarian carcinoma with carboplatin hypersensitivity: report of three cases. Tumori 2003; 89: 311-3
108. Kechijian P, Sadick NS, Mariglio J, et al. Cytarabine-induced inflammation in the seborrheic keratoses of Leser-Trelat. Ann Intern Med 1979; 91: 868-9
109. Omura EF, Torre D. Inflammation of actinic keratoses due to systemic fluorouracil therapy. JAMA 1969; 208: 150-1
110. Epstein E. Does intermittent "pulse" topical 5-fluorouracil therapy allow destruction of actinic keratoses without significant inflammation? J Am Acad Dermatol 1998; 38: 77-80
111. Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol 1987; 17 (2 Pt 1): 192-7
112. Hardwick N, Murray A. Inflammation of actinic keratoses induced by cytotoxic drugs. Br J Dermatol 1986; 114: 639-40
113. Coppes MJ, Jorgenson K, Arlette JP. Cutaneous toxicity following the administration of dactinomycin. Med Pediatr Oncol 1997; 29: 226-7
114. Coldiron BM, Manders SM. Persistent Candida intertrigo treated with fluconazole. Arch Dermatol 1991; 127: 165-6
115. Halme M, Jekunen A, Tamminen K, et al. Phase II study of weekly gemcitabine in advanced non-small cell lung cancer. Respir Med 1997; 91: 423-6
116. Fitzpatrick JE. New histopathologic findings in drug eruptions. Dermatol Clin 1992; 10: 19-36
117. Yokel BK, Friedman KJ, Farmer ER, et al. Cutaneous pathology following etoposide therapy. J Cutan Pathol 1987; 14: 326-30
118. Wade TR, Ackerman AB. The effects of resin of podophyllin on condyloma acuminatum. Am J Dermatopathol 1984; 6: 109-22
119. Sinibaldi VJ, Carducci M, Laufer M, et al. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol 1999; 26 (5 Suppl. 17): 45-8
120. Ek T, Jarfelt M, Mellander L, et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 2001; 37: 459-64
121. Chng WJ. Cytarabine syndrome revisited [letter]. Br J Haematol 2003; 122: 875
122. Manoharan A. The cytarabine syndrome in adults. Aust N Z J Med 1985; 15: 451-2
123. Naidu MU, Ramana GV, Rani PU, et al. Chemotherapy-induced and/or radiation therapy-induced oral mucositis: complicating the treatment of cancer. Neoplasia 2004; 6: 423-31
124. Aranda E, Diaz-Rubio E, Cervantes A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998; 9: 727-31
125. Del Pozo J, Martinez W, Garcia-Silva J, et al. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol 2001; 11: 450-2
126. Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 2005; 16: 597-601
127. Picozzi VJ, Pohlman BL, Morrison VA, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001; 15: 1296-314
128. Ferrara F, Palmieri S, De Simone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234-41
129. Aguilar-Ponce J, Granados-Garcia M, Villavicencio V, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2004; 15: 301-6
130. Clarkson JE, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2003; (3): CD000978
131. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-8
132. Palifermin (Kepivance) for myelotoxic-therapy-related mucositis. Med Lett Drugs Ther 2005; 47: 36
133. Albares MP, Belinchon I, Pascual JC, et al. Subungal abscesses secondary to paclitaxel. Dermatol Online J 2003; 9: 16
134. Mackay-Wiggan J, Nair KG, Halasz CL. Onycholysis associated with paclitaxel. Cutis 2003; 71: 229-32
135. Leonard GD, Zujewski JA. Docetaxel-related skin, nail, and vascular toxicity. Ann Pharmacother 2003; 37: 148
136. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004; 9: 538-45
137. Dainichi T, Tanaka M, Tsuruta N, et al. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 2003; 207: 324-5
138. Curran CF. Onycholysis in doxorubicin-treated patients. Arch Dermatol 1990; 126: 1244
139. Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. Aus J Dermatol 2002; 43: 293-6
140. Piroth MD, Krempien R, Wannenmacher M, et al. Radiation recall dermatitis from docetaxel. Onkologie 2002; 25: 438-40
141. Friedlander PA, Bansal R, Schwartz L, et al. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer 2004; 100: 1793-9
142. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-8
143. Armstrong RB, Poh-Fitzpatrick MB. Methotrexate and ultraviolet radiation. Arch Dermatol 1982; 118: 177-8
144. Guzzo C, Kaidby K. Recurrent recall of sunburn by methotrexate. Photodermatol Photoimmunol Photomed 1995; 11: 55-6
145. Morkas M, Fleming D, Hahl M. Challenges in oncology: case 2. Radiation recall associated with docetaxel. J Clin Oncol 2002; 20: 867-9
146. Breza TS, Halprin KM, Taylor JR. Photosensitivity reaction to vinblastine. Arch Dermatol 1975; 111: 1168-70
147. Boman NL, Tron VA, Bally MB, et al. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother Pharmacol 1996; 37: 351-5
148. Arthur DW, Koo D, Zwicker RD, et al. Partial breast brachytherapy after lumpectoliposomal my: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys 2003; 56: 681-9
149. Groen HJ, Sleijfer S, Meijer C, et al. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br J Cancer 1995; 72: 1406-11
150. Solberg Jr LA, Wick MR, Bruckman JE. Doxorubicin-enhanced skin reaction after whole-body electron-beam irradiation for leukemia cutis. Mayo Clin Proc 1980; 55: 711-5
151. Venat-Bouvet L, Ly K, Szelag JC, et al. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003;14: 829-32
152. Geisler JP, Schraith DF, Manahan KJ, et al. Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer. Gynecol Oncol 2004; 92: 705-7
153. Dereure O, Navarro R, Rossi JF, et al. Rituximab-induced vasculitis. Dermatology 2001; 203: 83-4
154. Weinlich G, Schuler G, Greil R, et al. Leg ulcers associated with long-term hydroxyurea therapy. J Am Acad Dermatol 1998; 39 (2 Pt 2): 372-4
155. Nuver J, Gietema JA. Thromboembolic complications during cisplatin-containing chemotherapy for testicular cancer: a problem in the short and possibly also the long term. Ned Tijdschr Geneeskd 2003; 147: 428-30
156. Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72: 587-93
157. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A (13-14): 2229-38
158. Voorburg AM, van Beek FT, Slee PH, et al. Vasculitis due to gemcitabine. Lung Cancer 2002; 36: 203-5
159. Aragane Y, Okamoto T, Yajima A, et al. Hydroxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product. Br J Dermatol 2003; 148: 599-600
160. Kido M, Tago O, Fujiwara H, et al. Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline. Br J Dermatol 1998; 139: 1124-6
161. Uthman I. Pharmacological therapy of vasculitis: an update. Curr Opin Pharmacol 2004; 4: 177-82
162. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003; 62: 1230-3
163. Saigal K, Valencia IC, Cohen J, et al. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 2003; 49 (5 Suppl.): 283-5
164. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34
165. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002; 61: 922-4
166. Specks U, Fervenza FC, McDonald TJ, et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40
167. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 2002; 29 (5 Suppl. 14): 55-60
168. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003; 21: 99-101
169. Saltz LB, Meropol NJ, Loehrer Sr PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-8
170. Curran CF. Doxorubicin-associated facial flushing. Arch Dermatol 1992; 128: 1408
171. Skelton H, Linstrum J, Smith K. Host-vs.-altered-host eruptions in patients on liposomal doxorubicin. J Cutan Pathol 2002; 29: 148-53
172. Pascual JC, Banuls J, Belinchon I, et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004; 151: 1111-2
173. Gooptu C, Littlewood TJ, Frith P, et al. Paraneoplastic pemphigus: an association with fludarabine? Br J Dermatol 2001; 144: 1255-61
174. Ahmed AR, Avram MM, Duncan LM. Case 23-2003: a 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N Engl J Med 2003; 349: 382-91
175. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564-7
176. Senet P, Aractingi S, Porneuf M, et al. Hydroxyurea induced dermatomyositis like eruption. Br J Dermatol 1995; 133: 455-9
177. Pamuk GE, Turgut B, Vural O, et al. Metastatic squamous cell carcinoma of the skin in chronic myeloid leukaemia: complication of hydroxyurea therapy. Clin Lab Haematol 2003; 25: 329-31
178. Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol 2004; 51: 293-300
179. De Benedittis M, Petruzzi M, Giardina C, et al. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 2004; 29: 605-7
180. Van Cutsem E, Blijham GH. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. Semin Oncol 1999; 26 (1 Suppl. 5): 13-20
181. Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997; 24 (4 Suppl. 13): 3-10